The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The stability is led by healthy demand in the domestic and emerging markets
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
DCGI approved the drug based on the review of clinical data
2022 is going to be the year of opportunities and innovations from the medical industry in India
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Subscribe To Our Newsletter & Stay Updated
